BACKGROUND: Adult survivors of childhood cancer are at risk for long-term morbidities, which may be managed pharmacologically. Psychoactive medication treatment has been associated with adverse effects on specific neurocognitive processes in non-cancer populations, yet these associations have not been examined in adult survivors of childhood cancer. PROCEDURE: Outcomes were evaluated in 7,080 adult survivors from the Childhood Cancer Survivor Study (CCSS) using a validated self-report Neurocognitive Questionnaire. Multivariable logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CI) for neurocognitive impairment using demographic and treatment factors and survivors' report of prescription medication use. RESULTS: Controlling for cranial radiation, pain, psychological distress, and stroke/seizure, use of antidepressant medications was associated with impaired task efficiency (OR = 1.80, 95% CI = 1.47-2.21), organization (OR = 1.83, 95% CI = 1.48-2.25), memory (OR = 1.53, 95% CI = 1.27-1.84), and emotional regulation (OR = 2.06, 95% CI = 1.70-2.51). Neuroleptics and stimulants were associated with impaired task efficiency (OR = 2.46, 95% CI = 1.29-4.69; OR = 2.82, 95% CI = 1.61-4.93, respectively) and memory (OR = 2.08, 95% CI = 1.13-3.82; OR = 2.69, 95% CI = 1.59-4.54, respectively). Anticonvulsants were associated with impaired task efficiency, memory, and emotional regulation, although survivors who use these medications may be at risk for neurocognitive impairment on the basis of seizure disorder and/or underlying tumor location (CNS). CONCLUSIONS: These findings suggest that specific psychoactive medications and/or mental health conditions may be associated with neurocognitive function in adult survivors of childhood cancer. The extent to which these associations are causal or indicative of underlying neurological impairment for which the medications are prescribed remains to be ascertained.
BACKGROUND: Adult survivors of childhood cancer are at risk for long-term morbidities, which may be managed pharmacologically. Psychoactive medication treatment has been associated with adverse effects on specific neurocognitive processes in non-cancer populations, yet these associations have not been examined in adult survivors of childhood cancer. PROCEDURE: Outcomes were evaluated in 7,080 adult survivors from the Childhood Cancer Survivor Study (CCSS) using a validated self-report Neurocognitive Questionnaire. Multivariable logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CI) for neurocognitive impairment using demographic and treatment factors and survivors' report of prescription medication use. RESULTS: Controlling for cranial radiation, pain, psychological distress, and stroke/seizure, use of antidepressant medications was associated with impaired task efficiency (OR = 1.80, 95% CI = 1.47-2.21), organization (OR = 1.83, 95% CI = 1.48-2.25), memory (OR = 1.53, 95% CI = 1.27-1.84), and emotional regulation (OR = 2.06, 95% CI = 1.70-2.51). Neuroleptics and stimulants were associated with impaired task efficiency (OR = 2.46, 95% CI = 1.29-4.69; OR = 2.82, 95% CI = 1.61-4.93, respectively) and memory (OR = 2.08, 95% CI = 1.13-3.82; OR = 2.69, 95% CI = 1.59-4.54, respectively). Anticonvulsants were associated with impaired task efficiency, memory, and emotional regulation, although survivors who use these medications may be at risk for neurocognitive impairment on the basis of seizure disorder and/or underlying tumor location (CNS). CONCLUSIONS: These findings suggest that specific psychoactive medications and/or mental health conditions may be associated with neurocognitive function in adult survivors of childhood cancer. The extent to which these associations are causal or indicative of underlying neurological impairment for which the medications are prescribed remains to be ascertained.
Authors: Clifford S Calley; Gail D Tillman; Kyle Womack; Patricia Moore; John Hart; Michael A Kraut Journal: Cogn Behav Neurol Date: 2010-09 Impact factor: 1.600
Authors: D P Waber; S C Carpentieri; N Klar; L B Silverman; M Schwenn; C A Hurwitz; P J Mullenix; N J Tarbell; S E Sallan Journal: J Pediatr Hematol Oncol Date: 2000 May-Jun Impact factor: 1.289
Authors: Jeroen A J Schmitt; Johannes G Ramaekers; Monique J Kruizinga; Martin P J van Boxtel; Eric F P M Vuurman; Wim J Riedel Journal: J Psychopharmacol Date: 2002-09 Impact factor: 4.153
Authors: M W van Laar; E R Volkerts; M N Verbaten; S Trooster; H J van Megen; J L Kenemans Journal: Psychopharmacology (Berl) Date: 2002-06-05 Impact factor: 4.530
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Norma Mammone D'Agostino; Kim Edelstein; Nan Zhang; Christopher J Recklitis; Tara M Brinkman; Deokumar Srivastava; Wendy M Leisenring; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Cancer Date: 2016-07-08 Impact factor: 6.860
Authors: Yin Ting Cheung; Tara M Brinkman; Chenghong Li; Yasmin Mzayek; Deokumar Srivastava; Kirsten K Ness; Sunita K Patel; Rebecca M Howell; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Natl Cancer Inst Date: 2018-04-01 Impact factor: 13.506
Authors: Nicholas S Phillips; Raja B Khan; Chenghong Li; Sedigheh Mirzaei Salehabadi; Tara M Brinkman; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull; Zsila S Sadighi Journal: Cancer Date: 2021-09-01 Impact factor: 6.860
Authors: Kelly M Kenzik; I-Chan Huang; Tara M Brinkman; Brandon Baughman; Kirsten K Ness; Elizabeth A Shenkman; Melissa M Hudson; Leslie L Robison; Kevin R Krull Journal: Neuropsychology Date: 2014-06-16 Impact factor: 3.295
Authors: Tara M Brinkman; Matthew J Krasin; Wei Liu; Gregory T Armstrong; Rohit P Ojha; Zsila S Sadighi; Pankaj Gupta; Cara Kimberg; Deokumar Srivastava; Thomas E Merchant; Amar Gajjar; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544
Authors: Satomi Sato; Nan Li; Stephanie B Dixon; Miho Kato; Hui Zhang; Chi Kong Li; Rebecca M Howell; Wendy M Leisenring; Smita Bhatia; Kevin C Oeffinger; Gregory T Armstrong; Yutaka Yasui; Kevin R Krull; Yin Ting Cheung Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-04 Impact factor: 4.254
Authors: Emily S Tonorezos; Jennifer S Ford; Linwei Wang; Kirsten K Ness; Yutaka Yasui; Wendy Leisenring; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger; Paul C Nathan; Gregory T Armstrong; Kevin Krull; Lee W Jones Journal: Cancer Date: 2019-05-08 Impact factor: 6.921
Authors: Fiona S M Schulte; Michaela Patton; Nicole M Alberts; Alicia Kunin-Batson; Barbara A Olson-Bullis; Caitlin Forbes; K Brooke Russell; Alexandra Neville; Lauren C Heathcote; Cynthia W Karlson; Nicole M Racine; Courtney Charnock; Matthew C Hocking; Pia Banerjee; Perri R Tutelman; Melanie Noel; Kevin R Krull Journal: Cancer Date: 2020-10-28 Impact factor: 6.860